Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $23.44 million. The enterprise value is $20.41 million.

Market Cap	23.44M
Enterprise Value	20.41M

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 20.74 million shares outstanding. The number of shares has increased by 35.56% in one year.

Current Share Class	20.74M
Shares Outstanding	20.74M
Shares Change (YoY)	+35.56%
Shares Change (QoQ)	+8.43%
Owned by Insiders (%)	37.39%
Owned by Institutions (%)	5.88%
Float	11.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.34
P/TBV Ratio	4.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.16

Current Ratio	7.16
Quick Ratio	4.49
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-35.83

Financial Efficiency

Return on equity (ROE) is -281.84% and return on invested capital (ROIC) is -137.88%.

Return on Equity (ROE)	-281.84%
Return on Assets (ROA)	-73.85%
Return on Invested Capital (ROIC)	-137.88%
Return on Capital Employed (ROCE)	-75.89%
Revenue Per Employee	n/a
Profits Per Employee	-$1.18M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.30% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-16.30%
50-Day Moving Average	1.31
200-Day Moving Average	1.05
Relative Strength Index (RSI)	45.43
Average Volume (20 Days)	393,613

Short Selling Information

The latest short interest is 274,895, so 1.33% of the outstanding shares have been sold short.

Short Interest	274,895
Short Previous Month	361,699
Short % of Shares Out	1.33%
Short % of Float	2.33%
Short Ratio (days to cover)	0.28

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.55M
Pretax Income	-4.71M
Net Income	-4.71M
EBITDA	-4.39M
EBIT	-4.55M
Earnings Per Share (EPS)	-$0.33

Balance Sheet

The company has $3.03 million in cash and n/a in debt, giving a net cash position of $3.03 million or $0.15 per share.

Cash & Cash Equivalents	3.03M
Total Debt	n/a
Net Cash	3.03M
Net Cash Per Share	$0.15
Equity (Book Value)	6.00M
Book Value Per Share	0.34
Working Capital	4.16M

Cash Flow

Operating Cash Flow	-5.34M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-35.56%
Shareholder Yield	-35.56%
Earnings Yield	-20.10%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $8.33, which is 637.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.33
Price Target Difference	637.17%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1